StemCell Therapy

In Costa Rica, pura vida has become much more than just a slogan; its a way of life. The popular expression, which translates to pure life, has been used by locals for decades as a casual way of saying everythings good or as a way to describe Costa Rican lifestyle and culture.

As the saying pura vida indicates, Costa Ricans certainly know a thing or two about living life to the fullest, as its the home to some of the longest-living people in the world. Nicoya, an 80-mile peninsula in Costa Rica just south of the Nicaraguan border, has been identified by longevity expert, bestselling author, and National Geographic researcher Dan Buettner as one of the five Blue Zones regionsaka the parts of the planet that are home to the oldest-living peopledue to its abundance of centenarians.

So, whats the key to healthy aging for many folks residing in the Nicoya Peninsula? Aside from maintaining a strong sense of purpose, feeling connected to their community, and moving throughout the day (as well as a number of other longevity-boosting lifestyle habits), Costa Ricans tend to consume a healthy diet comprised of a trifecta of super nutritious ingredients dubbed the three sisters, aka corn, beans, and squash. Weve gathered a few delicious, nutrient-rich three sisters recipes made with these ingredients that will bring a bit of pura vida to wherever you reside.

The three sister ingredientscorn, beans, and squashstem from the traditional Mesoamerican diet that many Nicoyan centenarians follow. People in this region tend to eat light dinners early in the evening, comprised of these simple, nutritious foods. Most meals in the Nicoya Peninsula incorporate plant-based, nutrient-dense, and protein-rich ingredients like legumes and vegetables (which make up about 21 percent of their diet), three sisters included.

According to Blue Zones research, squash, beans, and corn are grown together, eaten together, and celebrated together, as they provide a symbiotic growing relationship, as well as a complete nutritional profile. When growing, the corn provides a trellis for the beans, beans add nitrogen to the soil, and the squash shades out the weeds. Nature is incredible, right?

What's more, just like they complement and support one another as they grow in a field, the three sisters pair even more perfectly together when cooking delicious, nutrient-dense meals. Corn provides gut-healthy fiber plus tons of vitamins and phytochemicals that help combat inflammation in the body. Meanwhile, beans are rich in protein and fiber, and squash yields antioxidants, vitamins, and minerals, including vitamin A, calcium, magnesium, and a host of carotenoids. Plus, when consumed together, these plant-based foods form what's known as a complete protein, meaning they provide your body with all nine essential amino acids. And then there's the incredible versatile flavor profile of these foods; you'd be hard-pressed to find an ingredient that corn, beans, and squash don't pair with.

Ready to incorporate corn, beans, and squashthe perfect fall foodsinto your every dish? Read on for some delicious, easy to make three sisters recipes.

Photo: Veg Kitchen

While you certainly dont have to eat the three sisters ingredients together every single time, it may be one of the best ways to get the most amount of nutrients in one serving. If productivity is the name of the game, this easy three sisters stew recipe by Veg Kitchen might catch your attention. Its made with (you guessed it!) tender squash, protein-packed beans, and fresh corn and comes together in less than an hour. Aside from being a perfect hearty weeknight meal, it can also be the perfect veggie-forward side dish for Thanksgiving dinner, too.

Get the recipe: Three Sisters Stew

Photo: Simply Recipes

Just like the three sisters have the perfect symbiotic relationship when planted close to one another (as they have traits that nurture and help the others grow), this vegetarian three sisters casserole with cornbread topping recipe by Simply Recipes is a match made in heaven. Its packed with anti-inflammatory spices like chili powder and nutrient-dense greens like spinach or kale. Plus, the casserole gets finished with a delicious crunchy cornbread biscuit topping thats simply irresistible.

Get the recipe: Three Sisters Casserole with Cornbread Topping

Photo: Brand New Vegan

Fall is officially here, and that means cozy and comforting soups all season long. This simple three sisters stew recipe by Brand New Vegan can be made in just about half an hour and is just as nutrient-dense as it is delicious to eat. Aside from our favorite three sisters, this recipe also has other nutritious staple ingredients like lycopene-rich tomatoes and fiber-rich potatoes. So, the next time youre struggling with what to make for dinner (yet again), consider this dish your problem solved.

Get the recipe: Three Sisters Stew

Photo: Suwannee Rose

If your favorite cowboy caviar recipe got a major gut-healthy and protein-packed glow-up, it would definitely become this sisters harvest bowl recipe by Suwannee Rose. This delicious dish has our favorite longevity-boosting ingredients plus a healthy serving of grains (in this case, quinoa), which happens to be another one of the must-have foods Nicoyans eat on a daily basis. After all, on average, 26 percent of the Nicoyan diet is based on whole grains like quinoa. Plus, quinoa is also a great source of calcium and folate, and its full of fiber, with five grams per serving.

Get the recipe: Sisters Harvest Bowls

An herbalist shares a brain-boosting herbal shot for longevity:

Continue reading here:
4 Recipes With Corn, Beans, and SquashThe Three Sisters Ingredients That Blue Zone Centenarians in Costa Rica Eat Every Day - Well+Good

Trump cut short '60 Minutes' interview with Lesley Stahl

President Trump cut short an interview with '60 Minutes' correspondent Lesley Stahl and has since leaked the session before its Oct. 25 airing.

USA TODAY

NEW YORK Lesley Stahl doesn't back down.

The unflappable TV journalist has been with CBSfor 50 years 31 of those as a correspondent for venerablenewsmagazine "60 Minutes." In that time, she hasbecome known for her remarkable poise and dogged pursuit of the truth,refusing to throw softball questions to contentious interview subjects such as former President Donald Trump, who memorably cut shorttheir 2020 sit-down.

"A lot of heads of state have walked out on me," says Stahl, 80, sitting at her desk on a recent rainy morning after a workout. "I'm not saying I'm proud of it, but it does signify thatI'm not afraid to ask a question that a head of state isn't going to like. I see that as my role and I see their role as being accountable for their actions, whether they're a dictator orthe head of a democracy."

Lesley Stahl: How 'Marcel'landed '60 Minutes' correspondent for the perfect cameo

'60 Minutes': Top moments from Trump's combative interview with Lesley Stahl

Half a century into her CBS career,Stahl remains as vigorous and relevant as ever. For the 55thseason of "60 Minutes" (Sundays, 7 EDT/PDT),she traveled to Taiwan to report on how people are responding to the country'sheightened threat from China. After stopping home in New York for a day to repack her suitcase, she flew to Tehran to interviewIranian President Ebrahim Raisi.

"That would have anybody flat on their back, but she manages her time unbelievably well, and then she's on to the next thing," says Bill Owens, executive producer of "60 Minutes." "There's nobody I'd rather be in a foxhole with than Lesley Stahl. She's fearless and fair and one of the hardest working people I've ever met."

Stahl was hired by CBS News in 1972 as part of the network'saffirmative action program, along with journalists Connie Chung and Bernard Shaw. As a young reporter, she cut her teeth covering the Watergate scandal and impeachment hearings of President Richard Nixon, under the tutelage of Washington bureau chief William J. Small.

"I was lucky," Stahl says. "I felt very little of what you would call discrimination because I was a woman. The boss said, 'This is an important program, and we're all getting behind it.' And when the boss says it, it's in the air."

Before joining "60 Minutes" in 1991, she was a moderator for "Face the Nation," grilling dignitaries such as the U.K.'sprime minister, Margaret Thatcher, and former Secretary of State George Shultz, after theIran-Contra affair. These and other interviews earned her areputation of being tough a label that Stahl disputes.

"The word 'tough' is interesting to me because I've always been called tough," Stahl says. "I called up my dad once and said, 'Dad, they say I'm tough.' And he said:'You're not. Tough is firing someone.You've never had to do that.' So I'm not tough my dad said so. (Laughs.)I am persistent, and it's to a fault. I will ask (a question) five times and I've been metaphorically slapped around for it."

According to Nielsen, "60 Minutes" averages 9 million viewers a week, and ended the 2021-22 TV season as the No. 1 news program. Stahl believes the newsmagazine, which launched in 1968,has maintained a consistently large audience for decades because the format hasn't changed, with in-depth segments covering a broad spectrum of topics including politics, science and the arts.

"We're old-fashioned," Stahl says. "We still try our hardest to be unbiased and give all sides. And people have comfort when they see we haven't changed that clock is still there."

Stahl is unsure whether "60 Minutes" will be around for another 55 seasons. ("I don't know if we can become something on our phone," she explains. "Our pieces are 13 to 15 minutes long.") But she has no desire to leave anytime soon.

"I climbed a mountain last year. I was very proud of that," Stahl says, recalling a "grueling" shoot withmountain gorillas in Rwanda. "I'm always kind of examining myself now: Am I less sharp? Can I do this job physically? I remember going to (one of the show's producers) and saying:'When I feel like I'm losing it, I'll come to you. I'll be the one to march in here.' And he said:'No you won't. No one ever does that.'"

Stahl won a legion of young fans this summer thanks to her meta cameo in family film"Marcel the Shell with Shoes On," in which she interviewed the animated mollusk for a spot-on recreation of a "60 Minutes" segment. In the movie, released in June, Marcel is a Stahl superfan who praises her for having "class" and blowing cases "wide open" compliments that "embarrassed" the journalist the first time she watched the film. (She now has a 3D-printed Marcel "trophy" on her desk, with a plaque reading "Lesley Stahl is fearless" a quote from the movie.)

More than a dozen family photos adornher cozy Midtown office, the same one she hashad since shestarted at "60 Minutes." Some of her 13 Emmy Awards line the bookshelves,with file boxes of research tucked away on the floor.

"The last 30 years, I've lived in this room," Stahl says."They asked me if I wanted to move, and at first I said, 'Can I have a bigger office?' And then I thought, 'Well, I can't move. All my junk is here.'"

Stahl has one daughter, Taylor, and two grandkids, ages 9 and 11. Her husband, writer Aaron Latham, diedin July at 78 after a long battle with Parkinson's disease. They met while she was a reporter covering Watergate and were married in 1977.

"Everything that's happened to me has happened while I've been here (at CBS): my marriage, my children, my grandchildren," Stahl says. "And my career is a really central part of me, so this is my whole life, really."

Read the original post:
Lesley Stahl on longevity of '60 Minutes': 'That clock is still there' - USA TODAY

halioua began 2020 with $5.1 million in funding. By way of thanks she sent all of her investors, including Rosen, fluffy toy puppies wearing company bandanas. She secured an office on the edge of downtown San Francisco, but the lease began in March, the same month the Bay Area became the first part of the US to enter pandemic lockdown. Her companys formative months, and first hires, took place via Zoom, Slack, and eventually socially distanced meetups. Halioua raised another $6 million and hired scientists, veterinarians, and an expert in getting new animal drugs past the FDA.

She embraced the role of dog company CEOpainting a mural of a giant German shepherd in Loyals office and ordering shirts with the slogan Save the dogs, save the world. She adopted a fluffy white husky named Wolfie, whom she has described as her cofounder and Loyals chief evangelist. Her management style, she says, was informed by her bad experiences at Oxford. When she talks to her team about her goals or beliefs, she tries to pair her statements with evidence to convince her workers that the boss is being straight with them. Even if you dont trust me, you still know this is true, she says.

Haliouas new science team, including a scientist who previously led aging research at pharma giant Regeneron, helped refine her original idea. They identified a compound they believed could be given to young dogs of the largest breeds, such as French mastiffs, to delay their accelerated aging process. They found a second compound they thought could target processes that cause cognitive decline and kidney problems in older dogs of all sizes.

As her company gained traction, Halioua noticed certain patterns in her business interactions. She tried to recruit women investors but found it difficult because there werent many to ask. When she met with investors who were men, some would try to flip a business meeting into a date, and others would confidently explain science to her that she knew inside out. Mostly she brushed off such momentsher time at Oxford had lowered her expectations of those with more power and prestige than her.

She often felt different. Describing herself as an Oxford dropout helped convince people to take her seriouslynever mind that she had left her PhD in part due to dissatisfaction with a harassment investigation, a circumstance missing from the dropout tales of archetypal boy geniuses like Mark Zuckerberg. She listened to hundreds of Silicon Valley podcasts to try to learn the industrys patois. She trained herself to smile less and wrote in a blog post aimed at women entrepreneurs: I come off as more of a grump now, but I am a grump who has the money she needs to build her company.

In the spring of 2021, Halioua published a blog post about her Oxford PhD supervisor titled The Gifts of My Harasser, leaving him nameless. She described the paradox of one of her worst experiences laying a foundation stone for her later successes by teaching her to be skeptical of social hierarchies and institutional power. Its been two years since I left. I am not broken anymore, but I still feel the cracks, she wrote. His abuse shattered my preconceived notions of how the world worked and cleared a path I otherwise never would have found.

Read the rest here:
The Search for a Pill That Can Help Dogsand HumansLive Longer - WIRED

Supontis (PON) and Dogecoin (DOGE) are two very different coins.

One is a technical cryptocurrency created to improve the cross-chain transfer of various digital currencies like Ethereum, Binance, and Tron. The other is a meme coin that prides itself on seamless peer-to-peer transactions and a lively community.

Nonetheless, both have one thing in common. They are part of a growing change in the crypto economy that is not entirely focused on financial gain.

Because traditionally, investors immersed themselves in the crypto universe for the sole purpose of making a healthy return in the future.

And if you look at the trajectory of Bitcoin (BTC), the masses had a point. Less than one year ago, Bitcoin peaked at $67,549.74. This means that savvy investors who exchanged Bitcoin for fiat during this time walked away with a huge profit.

Indeed, the goal of making money from crypto is unlikely to cease. But its fair to say that not all crypto geeks are actively looking to withdraw their finances. In actuality, some people want a bit of crypto to remain in their wallet for trading or communal purposes.

The interesting predicament now is, which type of modern crypto will trend in the market for the longest time? Will investors continue to gravitate towards meme currencies or will more technical coins be better off in the long run?

Dogecoin is statistically the most popular meme coin of all time. At the time of writing, it is ranked number 10 on coinmarket and possesses a market cap of $7,915,648,509.

Its funny how Dogecoin started as just a meme. No one in the crypto world expected it to become so lucrative until an extremely rich and famous dude known as Elon Musk, decided to tweet about the coin in April 2019 and the rest is history.

Dogecoin undoubtedly gained a massive boost from the multi-billionaire. Nevertheless, the coin deserves credit for offering its users enough value from super fast and cheap transactions to keep them invested.

In contrast to Dogecoin, Supontis was not invented as a meme.

The cryptocurrency consists of a bridge platform that is built on the BNB Smart Chain and facilitates the cross-chain transfer of different assets. This is ideal for crypto nerds who like to seamlessly move their coins from one market to another.

But this is just the tip of the Supontis tsunami. Supontis also provides its users with a high level of security, extremely fast transactions, and low transaction costs.

Supontis quick transaction speeds are particularly notable as this allows it to compete with the likes of Dogecoin and Solana.

Final Thoughts

Supontis and Dogecoin both represent coins that deviate away from cryptocurrencys original concept.

You only need to look at Dogecoins market cap to see that it has no shortage of investors. However, the currency is experiencing a downward trend which could imply that individuals are moving away from meme coins.

Meanwhile, Supontis is still very new on the crypto scene and may have better potential. After all, with crypto on the rise, the need for easy and smooth exchange between different currencies is becoming more crucial.

If you would like further information about Supontis, check out the links below:

Presale: https://register.supontis.com

Website: http://supontis.com/

Telegram: https://t.me/SupontisTokenOfficial

Disclaimer: This is a press release post. Coinpedia does not endorse or is responsible for any content, accuracy, quality, advertising, products, or other materials on this page. Readers should do their own research before taking any actions related to the company.

Was this writing helpful?

Originally posted here:
Supontis vs Dogecoin, Which Cryptocurrency Has Greater Longevity In The Market? - Coinpedia Fintech News

It is with heavy hearts that the Louisville Zoo announces the passing of female western lowland gorilla Helen.

Affectionately called the Grand Dame of the gorilla world, Helen was much celebrated at 64 years old. She long impressed Zoo fans with her big personality and longevity.

Helen had been on quality of life watch and was in natural age decline for several months. Zoo caregivers made the difficult decision to euthanize Helen Friday.

At 64, Helen enjoyed remarkably good health for most of her life, with only expected age-related arthritis and some periodontal disease. However, she recently developed increasing instability and tremors. This put her at greater risk of falling which impacted her day-to-day welfare.

A typical median life expectancy for a female zoo gorilla is about 39 years. Helens longevity is only matched by Fatou, a gorilla at Zoo Berlin that is 65 years old.

The title Grand Dame was bestowed on Helen because of her senior status and for her honored role as a mother of three, a grandmother of 17, a great-grandmother of 21, a great-great-grandmother of 8, and finally, a great-great-great-grandmother of one. Two of her progeny, Bengati (great-grandchild) and Kindi (great-great-grandchild) reside at the Louisville Zoo.

Letting go of a special gorilla like Helen is very hard, but it is often the last, best thing we can do for our animals, said Louisville Zoo Director Dan Maloney. Helens exceptional longevity is not only a testament to her personal constitution, but also to the outstanding care provided by her keeper team and the animal health care staff over these past 20 years. Helen was one of our most beloved ambassadors. Her fascination with human babies delighted families for decades. I know our friends and members will share in her loss and miss her greatly.

Helen was a legend and she deserved the best, said Louisville Zoos Senior Veterinarian Dr. Zoli Gyimesi. Besides the Zoos staff that cared for her daily, she had her own dentist, cardiologist, gynecologist, neurologist, and orthopedist/pain manager. Helen taught us much about gorillas and geriatric gorilla care.

Helen inspired us all with her longevity, added Kristen Lucas, Ph.D. and Chair of the Gorilla Species Survival Plan with the Association of Zoos and Aquariums. She touched the lives of many people over the years, including those who cared for her and those who just spent time visiting her at the Zoo. She was an independent spirit as well as being an integral member of her gorilla family, and her legacy lives on.

Helen came to the Zoo in 2002 from Lincoln Park Zoo. Because she was wild born in West Africa (Cameroon), her birth year was estimated as 1958. The Louisville Zoo recognized Helens birthday annually in January to celebrate her being the oldest gorilla in North America and the second oldest gorilla in the world.

More:
Louisville Zoo says goodbye to one of world's oldest gorillas - Evening News and Tribune

As the prices of pretty much everything are creeping up,Express.co.ukspoke to a dietician about budget-friendly foods that can also boost your longevity. While theres no secret recipe for longer life, one key approach to longevity lies in staving off the precursors of chronic disease. From a lower risk of stroke to a reduced risk of heart disease, some cheap foods do this with gusto.

While its no secret that colourful fruit and veg as well as fibre-packed pulses are some of the healthiest foods out there, these longevity staples can be often taxing on your wallet.

Fortunately, Karine Patel, private dietitian and founder of Dietitian Fit & Co, has shared how to keep your budget tight and your body healthy during the ongoing cost-of-living crisis.

Patel said: Contrary to what we often hear, eating healthy doesnt need to be expensive.

You can create a multitude of healthy meals on a low budget while prolonging your lifespan.

READ MORE:The 'first noticeable' sign that cholesterol is dangerously clogging your arteries

The expert listed some of the cheapest foods you can get in the UK supermarkets, while also adding a few years onto your lifespan.

Patel said: According to a study, published by researchers at Harvard, eating three portions of vegetables and two servings of fruits daily is associated with a lower risk of premature death.

Whats more, the process of freezing doesnt strip the colourful, nutritious foods of any goodness, the expert explained.

While cheesy chips wont do much good for your arteries, theres no need to ditch potatoes altogether.

In fact, the starchy vegetable packs potassium, which can reduce your risk of a stroke and prolong your lifespan, according to the dietician.

She said: [Plus,] they are a long-lasting food, and they are usually less than 1/ kg."

Another popular side dish, rice can be bought for as little as 45p/kg and served with plenty of veggies.

Patel said: According to the Blue Zones (areas in the world where people tend to live longer lives), 65 percent of their diet consists of rice, which makes it one of the healthiest and cheapest dishes.

READ MORE:Golden milk can shorten the time it takes to fall asleep and make you sleep longer

While pasta in a rich sauce is considered pretty indulgent, switching up your regular choice for a wholewheat option could do plenty for your health.

Patel said: Wholewheat pasta is rich in fibres, and regular consumption of fibres is associated with lower risk of cardiovascular disease, which in turn reduces the risk of mortality."

Extremely cheap and so versatile, beans are an excellent source of fibre and protein.

The dietician added: They are a staple among people who live the longest lives, multiple studies suggest that consuming beans could prolong your life expectancy by multiple years.

Last but not least, tomatoes offer vitamin C, potassium, folate, as well as vitamin K.

The juicy fruit is also one of the best sources of carotenoid, an antioxidant that has been shown to protect against age-related disease.

From fragrant curries to warming stews, the expert suggested that you can make a variety of dishes perfect for winter, using these cheap ingredients.

Patel added: Always look at the unit pricing to check the price of a food for a specific unit of weight (or volume).

It helps to compare the real price difference between products. This will tell you how much youre paying per gram or kg (or ml) so you can compare packages and get the best deal.

Originally posted here:
'Prolong your lifespan': 5 'cheapest' foods that can boost longevity - Express

MINNEAPOLIS, October 12, 2022--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE, recruited its first distribution partner, California-based BGA Insurance, to begin rolling out Life Insurance Designed to Keep You Alive to agents across the state. FOXO also announced the appointment of James Grauel, Jr. as Chief Distribution Officer ("CDO") of FOXO LIFE to spearhead the launch of longevity-focused life insurance products with independent agents.

FOXO LIFE is partnering with leading independent insurance agencies across the United States who share its vision and goal of modernizing the industry. Grauel joins the team with decades of experience working in the life insurance industry from both the carrier and independent agent distribution viewpoints. As CDO, Grauel will manage the development of FOXO LIFEs network of independent agents selling longevity science-powered life insurance.

"I am thrilled to join a team that is building the most exciting thing Ive seen in this industry over the course of my career," said Jim Grauel, Jr., Chief Distribution Officer of FOXO LIFE. "Creating more value for life insurance consumers by aligning their healthy longevity with the natural financial interest of life insurance carriers is an incredible and obvious innovation the industry needs."

FOXO LIFE will be holding its first agent distribution rollout events in Southern California with BGA Insurance, its first broker-general agent, who represents over 4,000 independent agents who are now able to sell life insurance products with FOXO LIFEs Longevity Report.

Story continues

"We are excited to work with FOXO LIFE to bring our agent base the opportunity to reframe the life insurance conversation from death protection, to life, health, and longevity," said Barry Zimmerman, President. "The real game changer will be when FOXO LIFE introduces saliva-based underwriting protocols to mitigate the need for blood and urine specimen collection."

FOXO LIFEs first agent recruitment events will be held:

October 19th in Huntington Beach

November 1st in San Diego

November 2nd in Los Angeles, El Segundo

November 3rd in Sacramento, Roseville

For agents interested in attending an event contact Alicia at sales@foxolife.com or 888.405.8957.

"We like to say that FOXO LIFE was created by agents, for agents," said Jon Sabes, Founder and CEO of FOXO. "This means that the products and services we are bringing to market are designed to address major industry pain points that fall most directly on agents. Making it easier and more exciting for agents to sell life insurance is our first order of business."

Todays news comes four weeks after FOXO became a publicly traded company on the New York Stock Exchange American under the symbol "FOXO" via its merger with Delwinds Insurance Acquisition Corp ("Delwinds"), valuing the combined company at an estimated enterprise value of $369 million.

About FOXO Technologies Inc. ("FOXO")

FOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurances consumer value proposition with the FOXO Longevity Report. For more information about FOXO, visit http://www.foxotechnologies.com. For more information about FOXO LIFE, visit http://www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors/.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended or an exemption therefrom.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words "anticipate," "believe," "could," "expect," "estimate," "future," "intend," "strategy," "may," "might," "strategy," "opportunity," "plan," project," "possible," "potential," "project," "predict," "scales," "representative of," "valuation," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXOs business, and changes in the combined capital structure, (ii) the ability to implement FOXOs business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXOs intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXOs prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under "Risk Factors" therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005349/en/

Contacts

Contacts / Investor Relations Cody Slach, Matthew HauschGateway Investor Relations(949) 574-3860FOXO@gatewayir.com

Visit link:
FOXO Technologies Announces First Distribution Partner and Begins Product Rollout in California; Expands Executive Team With Insurance Industry Talent...

Fri, 10/14/2022 - 09:08am | By: David Tisdale

Left: USM English Professor Dr. Angela Ball is presented a portrait of the Aubrey K. Lucas Administration Building by USM College of Arts and Sciences Dean Dr. Chris Winstead, a gift signifying 40 or more years of service, along with induction into the universitys Centennial Legacy Circle Right: USM Art Professor Jim Meade is presented his 50-year service pin by USM College of Arts and Sciences Dean Dr. Chris Winstead.

A teacher affects eternity; he or she can never tell where their influence stops. Henry B. Adams

Long before social media, cell phones and Zoom meetings expanded the physical spaces between us, University of Southern Mississippi (USM) Professors Angela Ball and Jim Meade began establishing an in-person legacy cementing their reputations as among the best to hold forth in a classroom at the institution.

Meade came to the USM Hattiesburg campus in 1971 to join the faculty of its then Department of Art, as an assistant professor, with Dr. Ball following at the close of the decade as a visiting instructor of English in 1979. Together they have logged nearly 100 years in classrooms at the institution, and this fall resisted yet again the siren call of retirement, returning to do what they love most - teaching and inspiring their students products on canvases and through the written word.

For Meade, the pathway in life that led to USM wasnt easy. He grew up in poverty, and the tragic deaths of close family members in his teen years left him with the responsibility for three younger siblings. But he found great joy during that time as a Boy Scout in teaching the lessons of scouting to his younger cohorts in their quest for badges, along with working as a swimming instructor during the summer months. These experiences, he says, eventually revealed for him a career he felt suited for and wanted that of an educator - and his passion for it has not waned, even in the autumn of his life.

After studying for two years at the University of Virginia-Wise, Meade transferred to East Tennessee State University, where he earned bachelors and masters degrees in art before attaining an MFA from the University of Georgia. He has studied under established international artists, and his work has been on display in approximately 140 exhibitions, including 40 one-man shows and 17 overseas. Hes also lectured at universities in Asia and Europe.

As he pondered his job options upon approaching graduation at ETSU, one of Meades professors, Morton Brown, shared some sage advice.

The real action in higher education is at the state universities, Brown told him. These kids heading to the elite private schools - Harvard, Yale, Princeton - theyve got everything already education, money, privilege. Even if they dont graduate from college, they can fall back on their familys wealth or make their way in life through their talent, political, and economic connections.

The majority of our (ETSU) students are blue collar, working-class, first-generation college students much like those at other state (public) universities, Brown continued. These are the students working their way up from less privileged circumstances, and at these schools you get an opportunity to be a part of their success story.

USM Art Professor Jim Meade confers with a USM art student about the collection of compositions she will include in her senior project.

Meade feels USM holds a similar profile, and hes proud of his own students from the same kind of backgrounds who have gone on to paint self-portraits of success.

Many of the kids Ive taught here over the years are now living all around the world, enjoying interesting and rewarding careers in the arts, he said. Its gratifying to see what theyve accomplished.

As for his teaching philosophy, Meade says it is important to set the terms for instruction and be honest and consistent with your students.

Voltaire (the French philosopher) once said Gentlemen, define your terms. Well, teaching is a kind of deviation of that expression, Meade said. As an educator, I believe you should define the terms that make up your instruction and stay in the boundaries of those terms. I spend a good bit of the first part of a semester defining the terms.

Dr. Ball is a member of the USM English Programs prestigious Center for Writers faculty. She holds a bachelors degree from Ohio University, and MFA in Creative Writing (poetry emphasis) from the University of Iowa, and a Ph.D. from the University of Denver.

From 2013 to 2015, Dr. Ball was USMs Moorman Distinguished Professor of Humanities. Her extensive vita includes six volumes of poetry and hundreds of individual poems in prestigious publications such as the New Yorker and the Atlantic Monthly. She has served as editor of the Mississippi Review and as a Poet-in-Residence at the University of Richmond; shes been listed in Whos Who of American Writers and Editors and included in the Best American Poetry anthologies. She earned the Susan B. Herron Award for highest ranked fellow by the Mississippi Arts Council, along with multiple awards from the Mississippi Institute of Arts and Letters.

I'm as dumbfounded as anyone that I have been doing this for so long, she said. But I enjoy meeting the students and feel grateful every day for the immense variety of them that we have, both undergraduate and graduate students. It's particularly great to see some who perhaps struggled in the past to open up, like slightly late blossoms, to reading and learning.

I find if I encourage them to respond honestly to the readings, good things are bound to happen. There's a constant back-and-forth of ideas and inspiration, most intensely with the graduate poets and writers, but also often with undergraduates.

Dr. Ball recounts when, for an advanced composition class, she gave an assignment based on Studs Terkel's book of interviews, Work. A student in that class interviewed a sanitation worker, who at length extolled the virtues of his job: good pay and benefits, and best of all, you are always finding stuff! People throw out lots of valuable things. This is one of the best interviews I've read anywhere.

It's experiences like these and others that bring Dr. Ball back to the classroom, what she sees as opportunities to get out of myself, be surprised, help, and learn.

I come back to get out of myself -- to avoid a tendency to brood and/or feel sorry for myself, she said. My life, like most people's, has had a measure of heartache and I would much rather hear my students' poems, essays, and class discussion than give in to that.

This past August, Dr. Ball taught an intersession class in world literature, and a student woke her up to a detail in a story she has taught several times, misreading it because she had previously ignored it.

The same class was asked, on the example of Jamaica Kincaid's brief story, "Girl," to impersonate a parent giving harsh advice, Dr. Ball continued. A Black student read an inspired list of things to avoid doing as a young Black man, a list that ended up dauntingly long. The class responded with a burst of appreciative finger-snaps.

And there's nothing more satisfying for her as a teacher, she explains, than finding out a poem shes helped a student edit has been published, or even an entire dissertation.

But yet, maybe there is something more satisfying, she reconsidered. To see a light go on somewhere inside a student who has struggled with writing and sees, "Yes, I can say things simply and clearly. "

Dr. Angela Ball discusses the latest assignment with students in a USM Center for Writers fall 2022 graduate seminar.

Kevin Walters, a Hattiesburg native and two-time graduate of USM who lives in Nashville, says a day does not go by that hes not benefitted in some way -- either directly or indirectly -- from what he learned in the classes he took from Professors Ball and Meade.

Professor Ball's poetry classes -- particularly those focusing on the work of poet Elizabeth Bishop -- broadened my perspective about art, writing, and the world in ways I had never experienced before. Similarly, Professor Meade was the kind of instructor who enlightened you about the history of art, even as he pushed you to do more and better drawings yourself.

I would be remiss if I did not mention their accomplishments outside the classrooms, and how their work as artists fed what they taught in their classes.

Earlier this year, Meade and Dr. Ball were recognized for their years of service to the university in an event hosted by the USM Department of Human Resources, where Dr. Ball was presented a portrait of the Aubrey K. Lucas Administration Building, a gift signifying 40 or more years of service, along with induction into the universitys Centennial Legacy Circle; Meade was presented his service pin for 50 years-plus as a faculty member. The ceremony had been delayed due to the COVID-19 gathering restrictions of the last two years.

I so appreciated the lovely ceremony where the wonderful Jim Meade and I were recognized, Dr. Ball said. To be lauded for doing what we love is indeed lucky.

I will treasure the special portrait of the Dome given to me. In my imagination it is a portrait of me standing in front of a blackboard - or a white board - marveling at what my students have to say.

USM President Emeritus Dr. Aubrey K. Lucas says hes honored to count Meade and Dr. Ball as treasured colleagues and friends from their time together at the university.

Theyre both great artists and effective teachers, and certainly deserving to be honored for their exemplary work over the years as senior members of our faculty, Dr. Lucas continued.

Reflecting on his half century-plus career at USM, Meade has no regrets. I wouldnt change a thing, he said, adding that he hasnt set a date for calling it quits.

Ive done it for so long, I dont think I can break the habit. I really cant imagine doing anything else.

Read the rest here:
Timeless: USM Arts and Sciences Faculty Members Ball, Meade Cite Love for Students, Teaching as Keys to Longevity in Profession - The University of...

Understanding Gestational Diabetes

Gestational diabetes can be a scary diagnosis, but like other forms of diabetes, its one that you can manage. It doesnt mean that you had diabetes before you conceived or that you will have diabetes after you give birth. It means that, by working with your doctor, you can have a healthy pregnancy and a healthy baby. No matter what, know that you have all the support you need for both you and your baby to be at your best.

We dont know what causes gestational diabetes, but we know that you are not alone. It happens to millions of women. We do know that the placenta supports the baby as it grows. Sometimes, these hormones also block the action of the mothers insulin to her body and it causes a problem called insulin resistance. This insulin resistance makes it hard for the mothers body to use insulin. And this means that she may need up to three times as much insulin to compensate.

The key to treating it is to act quicklyas treatable as it is, gestational diabetes can hurt you and your baby. Work with your doctor to keep your blood glucose levels normal, through special meal plans and regular physical activity. Your treatment may also include daily blood glucose testing and insulin injections.

Read More on Gestational Diabetes

In addition to type 1, type 2, and gestational diabetes, a small minority of people develop specific types of diabetes due to other causes. This includes:

Because these types of diabetes are rare, they are often misdiagnosed as other types of diabetes. You can learn more about these types of diabetes in the Classification and Diagnosis of Diabetes section in the Standards of Medical Care in Diabetes. If you think you might have one of these types, be sure to talk with your doctor.

More on Diabetes from Other Causes

When it comes to prediabetes, there are no clear symptomsso you may have it and not know it. Heres why thats important: before people develop type 2 diabetes, they almost always have prediabetesblood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. You may have some of the symptoms of diabetes or even some of the complications.

See the article here:
Diabetes Symptoms, Causes, & Treatment | ADA

More than 11% of Americans have diabetes, which occurs when the pancreas does not produce enough insulin to regulate blood sugar levels.

As a nutritionist who has been living with type 1 diabetes for more than 30 years, I've found that having diabetes doesn't mean you have to completely stop eating what you enjoy. Managing blood sugar is often more about making small food swaps, or adding, rather than eliminating, certain foods.

For example, you can still eat carbs, but you also need to add protein, a small amount of healthy fats and plenty of fiber. Protein, fat and fiber all moderate how quickly food is digested, which is helpful in balancing blood sugar levels.

Here are the foods I eat and the foods I try to cut back on to help manage my diabetes:

Turning vegetables into noodles using a spiralizer is a great way to increase your fiber and vitamin intake.

Floortje | Getty

Wheat-based pasta is mostly carbohydrates, and it can lead to a blood sugar spike if eaten in large portions on its own.

Instead, I'll opt for bean-based pasta or a vegetable pasta. Turning vegetables (e.g., carrots, zucchini and sweet potatoes) into noodles using a spiralizer is a great way to increase your fiber and vitamin intake.

If you do choose to eat traditional pasta, whether it's gluten-free or wheat-based, be sure to add lots of protein and fiber to your dish. I recommend poultry, fatty fish like salmon and beans, and vegetables like kale, peppers, onions and broccoli.

As a substitute for grain rice, try riced broccoli, mushrooms, zucchini, chickpeas or cauliflower. These are fiber-rich and gentler on blood sugar.

Cavan Images | Getty

As a substitute for grain rice, try riced broccoli, mushrooms, zucchini, chickpeas or cauliflower. These are fiber-rich and gentler on blood sugar.

Brown rice is a common substitute for white rice in diabetes diet plans, but the carbohydrate amounts in both are actually pretty similar. And the small amount of additional fiber you get from brown rice isn't typically enough to have a significant impact on blood sugar levels.

So, just as with pasta, when you want to enjoy some rice, just be mindful of your portion size and pile on the protein, fat and fiber (e.g., from nuts, veggies, fish, or beans).

To make these chocolate chip almond butter breakfast bars, I use a combination of ground up oats (or oat flour) and almond flour. This combo creates a more blood sugar-friendly flour that also gives a great fluffy texture!

Mary Ellen Phillips

Instead of using traditional flour when baking or cooking, I'll opt for blood sugar-friendly flour made from almonds, coconuts or oats.

One of my favorite tricks is to use a blend of almond flour and oat flour. The resulting flour is lower in carbohydrates and higher in fiber and protein than wheat flour.

And it's equally tasty: This chocolate chip almond butter breakfast bars recipe is delicious!

Breakfast cereal can do a number on your blood sugar if you're not careful. Instead of choosing cereals with large amounts of added sugars, opt for brands that have more fiber and protein.

ATU Images | Getty

Breakfast cereals can do a number on your blood sugar if you're not careful. Instead of choosing cereals with large amounts of added sugars, choose brands that have more fiber and protein.

My recommendation for a high-fiber, low-sugar option: bran flakes. With about five grams of fiber per serving, this type of cereal contains 19 grams of net carbs per 3/4th cup serving, making it lower in carbohydrates than many breakfast cereals.

A bonus: The added fiber is beneficial to digestive health, heart health and weight management.

Berries are delicious and also low in sugar.

Viktoryia Vinnikava | Twenty20

Many people with diabetes are told they should avoid fruit. But there's often no reason to eliminate entire food groups, especially something as nutritious and tasty as fruit.

I always go for fruits low in sugar, such as berries, kiwi, melon and citrus. Watermelon is great, too, if consumed in moderation. One cup of diced watermelon has less than 10 grams of sugar.

If you want to eat fruits that are higher in sugar like bananas or mangos, enjoy them with a source of protein, like peanut butter, cheese or plain yogurt.

Mary Ellen Phipps is a registered dietitian, nutritionist and founder ofMilk and Honey Nutrition. She is also the author of "The Easy Diabetes Desserts Cookbook: Blood Sugar-Friendly Versions of Your Favorite Treats," and a writer forHealthDay. Follow her onTikTokandInstagram.

Don't miss:

Read more:
A nutritionist with type 1 diabetes shares the top 5 'food swaps' she eats to manage her blood sugar - CNBC

Diabetes is characterized by insufficient production of insulin due to the loss or dysfunction of pancreatic beta cells.

A new study published in Cell Metabolism shows that a protein called beta cell expansion factor A (BefA) secreted by gut bacteria could induce the replication of insulin-producing beta cells in neonatal mice.

Understanding the mechanisms underlying the actions of BefA protein could help develop therapies to stimulate beta cell proliferation in individuals with diabetes.

The study also provides a potential explanation of how the gut microbiome could play a role in the development of diabetes.

Study author Dr. Karen Guillemin, a professor at the University of Oregon in Eugene, told Medical News Today:

[Our findings imply] that the activities of gut bacteria in young animals including possibly humans can shape the development of the pancreas in early life. This is important because early life corresponding to about the first 2 years of life in a human is when insulin-producing beta cells are most proliferative, after which they become more quiescent. If this population of beta cells does not proliferate enough during early life, it means that the individual with a small beta cell pool is more vulnerable to developing type 1 diabetes if beta cells are depleted by autoimmune attack.

Dr. Martin Blaser, a professor in the Departments of Medicine and Pathology and Laboratory Medicine at Rutgers University, NJ, commented that this study is exciting because it represents a novel way that we might be able to regrow beta cells in situations with injury like type 1 diabetes.

This is a great example of how basic research on the microbiome of zebrafish can lead to new approaches to treating important human diseases, he added.

Individuals with type 1 diabetes are unable to regulate blood sugar levels due to the loss of insulin-producing beta cells in the pancreas. The loss of beta cells in type 1 diabetes is caused by an autoimmune response against these cells.

In contrast, in type 2 diabetes the body is initially able to produce insulin but the cells in the body do not respond to insulin. In response to the consequent increase in blood glucose levels, beta cells produce more insulin to compensate for the resistance of cells to the hormone. This leads to the exhaustion of beta cells and their dysfunction, resulting in lower insulin levels.

The replication rate of beta cells is high immediately after birth but rapidly declines thereafter. Thus, therapies that stimulate the replication or regeneration of beta cells in adults could help treat diabetes.

The studys authors had previously identified such a protein, called BefA, secreted by gut microbes that could stimulate the proliferation of beta cells in zebrafish.

Moreover, the authors had also identified a version of the BefA protein synthesized by gut bacteria in humans that could stimulate the proliferation of beta cells in zebrafish. In other words, the BefA proteins secreted by gut microbes in humans and zebrafish share a similar structure and function.

In the present study, the researchers further examined the mechanism through which BefA could facilitate the proliferation of pancreatic beta cells in young mice and zebrafish.

Previous studies have shown that the gut microbiome could potentially play a role in the development of diabetes. In their previous work, the study authors had shown that germ-free zebrafish larvae, which show a complete absence of gut microbes, show lower levels of pancreatic beta cell proliferation during development.

In addition, exposure to BefA prevented this decline in beta cell proliferation in germ-free zebrafish larvae.

In the current study, the researchers examined whether the BefA protein performed a similar function in mice. Specifically, they examined the impact of BefA in germ-free and specific pathogen-free (SPF) mice.

SPF mice are reared so that they are not exposed to disease-causing microorganisms that may interfere with the goals of the study.

Similar to germ-free zebrafish larvae, germ-free neonatal mice and SPF mice treated with antibodies at birth showed lower levels of beta cells than untreated SPF.

Notably, the BefA protein was able to rescue beta cell development in germ-free and antibody-treated SPF neonatal mice. Moreover, mice treated with BefA also showed lower blood glucose levels than untreated animals.

The researchers then examined whether the BefA protein could directly interact with beta cells to stimulate their expansion instead of exerting these effects by interacting with other tissues. They cultured pancreatic tissue dissected from germ-free zebrafish larvae and mice pups in the laboratory and exposed the cells to the BefA protein.

The researchers found that the BefA protein was able to directly interact with and stimulate the proliferation of pancreatic beta cells.

In subsequent studies using zebrafish larvae, the researchers examined how BefA protein synthesized by gut microbes could reach the beta cells in the pancreas. The BefA protein could be transmitted to the pancreas via the bloodstream or the hepatopancreatic duct, which connects the pancreas to the gut.

Using zebrafish models with a compromised hepatopancreatic duct or lacking blood vessels, the researchers found that pancreatic beta cell proliferation was reduced in both models.

These results show that BefA protein produced by intestinal microbiota could indeed travel from the intestine via the hepatopancreatic duct or blood vessels to reach the pancreas.

To better understand the function of the BefA protein, the researchers examined the structure of the protein. They found that BefA proteins derived from the bacterial species Klebsiella aerogenes in the human gut, and Aeromonas veronii in zebrafish showed considerable structural differences but shared an identical domain or region of the protein called SYLF.

The researchers found that the SYLF domain could rescue the loss of pancreatic beta cells in germ-free zebrafish larvae. These results suggest that this region could underlie the ability of the BefA protein to induce the proliferation of pancreatic cells.

Evidence from previous studies examining other proteins containing the SYLF domain from a wide range of organisms suggested that the ability of the BefA protein to stimulate beta cell proliferation may be mediated by its interaction with lipid membranes that surround cells.

Consistent with this, the researchers found that the BefA protein was able to permeabilize or disrupt synthetic membranes as well as membranes surrounding the cells of bacteria.

The secretion of BefA protein by certain gut bacteria could damage the cell membrane of other gut bacteria and confer a competitive advantage over these microbes. Moreover, this ability to disrupt cell membranes could also potentially explain the BefA proteins ability to enhance beta cell proliferation.

To test this hypothesis, the researchers exposed cultured pancreatic beta cells to a mutated form of BefA protein with a reduced ability to permeabilize membranes. The mutated BefA protein had a reduced ability to induce the proliferation of cultured pancreatic beta cells from neonatal mice.

These results suggest that the membrane permeabilizing activity of BefA was responsible for mediating its effects on beta cell proliferation. Proteins such as BefA may be secreted by gut microbes to gain a competitive advantage over other bacteria, but could also confer incidental benefits to the human host by facilitating normal pancreatic development.

However, Dr. Guillemin noted: We dont know yet whether BefA can stimulate proliferation of beta cells in older animals, in animals that have experienced beta cell autoimmune attack, or in people, but these are questions we are currently pursuing. We also dont know yet how membrane permeabilization stimulates beta cells to proliferate, but we are also pursuing this question.

In addition to the BefA protein synthesized by a subset of gut microbes, other proteins produced by human cells also possess membrane permeabilizing properties. This includes antimicrobial proteins that form pores in the membrane of bacterial cells and protect the body from harmful bacteria.

The researchers found that the Reg3 protein, a member of the antimicrobial protein family, was also able to increase the proliferation of mice and zebrafish pancreatic cells.

Proteins such as BefA that are produced during microbial competition are known to activate antimicrobial proteins. The study authors think that proteins secreted by gut microbes such as BefA and the antimicrobial proteins that are produced in response to these proteins could play an important role in the development of pancreatic beta cells.

These findings could facilitate the development of strategies for the prevention or treatment of diabetes. The diversification of the microbial communities in the gut occurs at the same time as the proliferation of beta cells after birth.

A lack of microbial diversity during early childhood, especially lower levels of microbes that secrete proteins such as BefA, could thus increase the risk of type 1 diabetes.

Dr. Guillemin explained:

There are several potential future therapeutic applications of our findings. One area is in prevention. It may be possible to perform microbiome profiling combined with other genetic and environmental data analysis to predict whether infants are at high risk for developing type 1 diabetes and if they may benefit from prophylactic administration of BefA-producing gut bacteria or BefA protein formulations to stimulate the development of their beta cell population in the first 2 years of life, which is when beta cells are most proliferative and when the lifelong pool of beta cells is established.

The second area is in the treatment of [type 1 diabetes], she added. It is possible that BefA will prove useful for stimulating the proliferation of beta cells in older individuals and in pancreases following the autoimmune destruction of beta cells, which is the process that causes [type 1 diabetes].

Even if BefA itself is not able to stimulate beta cell proliferation in these circumstances, our studies of the BefA mechanism may uncover new strategies to stimulate beta cell proliferation through membrane manipulations, said Dr. Guillemin.

The rest is here:
Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today

Newly Enhanced Danatech Website Includes CGM Insurance Lookup Tool

CHICAGO, Oct. 13, 2022 /PRNewswire/ -- All healthcare professionals caring for people with diabetes now have access to vital information about the latest diabetes technology in one place through the Association of Diabetes Care & Education Specialists' (ADCES) newly revamped danatech website.

Launched in 2018, danatech has been updated and enhanced. ADCES now provides free danatech access to all healthcare professionals, from the nurse who is trying to determine if insurance will cover a prescription for a continuous glucose monitor (CGM) to the provider who wants to compare the various insulin pumps to the radiologist who wants to know whether a patient should remove their device before having an MRI. Site visitors can also access training and education on the devices, including many for continuing education (CE/CME) credit. Many of these offerings are free.

"The number of people with diabetes is skyrocketing and there aren't nearly enough specialists to treat them all, healthcare professionals in multiple practice settings are caring for people with diabetes," said Leslie Kolb, DrPH, MBA. BSN, RN, chief science, practice and learning officer for ADCES. "But many are not familiar with the multitude of new technologies and devices available to those who need them the most. These technologies and devices generate the data that allows for effective care planning and danatech helps healthcare professionals get up to speed so they can collaborate with their patients most effectively to self-manage their diabetes."

The easy-to-navigate site includes information on apps and digital therapeutics designed to prevent, manage and/or treat diabetes and features:

"While some of these resources are available elsewhere, it's piecemeal, whereas danatech brings it all together," said Kolb. "For example, if a provider wants to compare insulin pumps to determine which would be best for a patient, they'd have to visit each of the manufacturer's websites individually. Now they don't."

Contact: Danielle McNary, 312-601-4805 [emailprotected]

SOURCE Association of Diabetes Care & Education Specialists (ADCES)

View original post here:
Providers Now Have Free Access to Latest Diabetes Technology in One Place - PR Newswire

MILTON When the COVID-19 pandemic hit, most children and young adults with Type 1 diabetes were unable to attend camps and other events geared toward their condition.

In order to make up for this, 19-year-old Adriana Richard of Milton along with 15-year-olds Natalie Brogan and Sophie Rinzler started T1D to the Third, which helps connect diabetic children and young adults through online events.

Richards was diagnosed with diabetes at age 5. Rinzler is from Chappaqua, N.Y., and was diagnosed with diabetes at age 4. Brogan is from Woodinville, Wash., and was diagnosed with diabetes in 2016.

T1D to the Third is a support group for type one diabetics around the world. Its goal is to provide a safe space for children and young adults with diabetes to interact.

Participants use Zoom calls to play games, host dance parties, do crafts and host "speed friending" events. The Zoom calls are monthly for three different age groups, 4 to 8, 9 to 12 and 13 to 20. There's also a pen pal program where, individuals pair with others from across the United States to chad about diabetes.

"We're kind of like a support group online to just make sure people are staying connected," said Richard.

T1D to the Third started when the three met each other at the 2019 JDRF (Juvenile Diabetes Research Foundation) Children's Congress. During COVID, they started the support group to compensate for the closed diabetic camps.

"It was super important during COVID-19 because there wasn't anything else out there for them," said Richard. "But now I think it is even more important because the world is starting to open back up and this bringing us back together even if it's just one time a month to hang out with each other and it's also connecting diabetics all over the world who might not have gotten to meet otherwise."

In the future, T1D to the Third hopes to do an in-person meet up at some point. The group is also interested in doing something special for National Diabetes Month in November.

Richard attends Shippensburg University, where she is studying special education and early childhood education to become an elementary school teacher. Her work with diabetes includes helping Cedar Crest College of Nursing run a diabetes day camp, andtestifying before the U.S. Senate Special Committee on Aging.

Richard hopes to follow her father Joshua Richard footsteps. He passed away in 2019 at age 39, and was known and well-respected for his nonprofit Walk On Foundation, which provided more than $100,000 in support to individuals suffering from various medical conditions.

"I feel like I'm a miniature him, following in his footsteps and trying to help people," said Richard.

Go here to see the original:
Milton teen involved in launch of diabetes support program - Milton Daily Standard

Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.

Among women with a history of gestational diabetes mellitus, modifying 5 different lifestyle risk factors was associated with a lower risk of type 2 diabetes (T2D), according to the results of a study published in The BMJ.

Investigators found that these results were seen even among individuals who were overweight, had obesity, or who have a greater genetic susceptibility.

Investigators included 4275 individuals with a history of gestational diabetes mellitus and respectively measured weight and lifestyle factors between 1991 and 2009. The data were self-reported, and the individuals were clinically diagnosed with T2D.

The 5 modifiable risk factors included not being overweight or having obesity with a body mass index of less than 25; a high-quality diet, which was calculated in the top two-fifths of the modified Alternate Healthy Eating Index; regular exercise of 150 minutes or more of moderate intensity or 75 minutes or more of vigorous intensity; moderate alcohol consumption, which was defined as 5 to 14.9 g/day; and currently not smoking.

After a median follow-up of 27.9 years, 924 of the 4275 women developed T2D. Individuals who had optimal levels of 5 factors had more than a 90% lower risk of developing T2D compared to individuals who did not have any optimal levels for of the risk factors for the disorder.

The hazard ratios of T2D for those with 1, 2, 3, 4, and 5 modifiable factors compared with 0 were 0.94, 0.61, 0.32, 0.15, and 0.08, respectively.

Among individuals with a body mass index of 25 or greater, the hazard ratio for achieving optimal levels of all other 4 risk factors was 0.40. Additionally, for women with higher genetic susceptibility, the hazard ratio of developing T2D for having 4 factors was 0.11, whereas in the group with all 5 factors there were no T2D events observed.

The genetic susceptibility for T2D was assessed by a genetic risk score based on 59 single nucleotide polymorphisms that were associated with T2D.

At baseline, investigators said that women who had optimal levels of 4 or more modifiable factors were more likely to be older at their first birth, have longer breastfeeding duration, were pre-menopausal, and were less likely to have a family history of diabetes.

Investigators said that limitations of the study included the self-reported modified risk factors as well as self-reported weight and lifestyle habits. They also said that the population consisted of mainly health care professionals of European ancestry, which could limit the application of these findings across other racial, ethnic, and socioeconomic groups.

They also noted that women who were aware of their risk for T2D and modified their risk factors may have also been more likely to get screened for T2D, therefore, the results could have underestimated the benefit associated with the modifiable factors in the study.

Reference

Yang J, Qian F, Chavarro J E, Ley S H, Tobias D K, Yeung E et al. Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study. BMJ. 2022;378 :e070312 doi:10.1136/bmj-2022-070312

Read more from the original source:
5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D - Pharmacy Times

Key Ingredients: A Story of Diabetes and Determination

BCMH Patient Story: Chantelle Mumma

Chantelle Mumma made a goal for herself when she learned she had Type 2 diabetes in August of 2021: to keep her blood glucose levels (or sugars) in check. She has achieved that goal, and as an added benefit, she has lost weight and gained more energy and self-confidence. It wasnt easy, but with her family history, she was highly motivated to get control of the disease.

Chantelle sought the help of her health care team at High Street Family Care Clinic right away. With the help of her nurse practitioner, Lori King, and other BCMH services and providers, Chantelle felt she was given the key ingredients that put her on a path to better health.

Nutrition Counseling

In the early days of any diagnosis, its normal to feel overwhelmed, and with diabetes in particular, there is a lot of information to digest. One of Chantelles first steps, on Lori Kings recommendation, was to get nutrition counseling, which she was able to schedule at BCMH with Jennifer Lindquist, RDN/LDN. Even with just one consultation, Chantelle felt she learned so much. One tip in particular laid the groundwork for her: count the carbs and the calories will fall into place.

I went in thinking; I dont know how Im going to do this. And when I left, I was like wait a minute, I think I can do this, Chantelle said.

I think prior to coming to see me, theres a lot of fear about being put on a restrictive diet, said Jennifer. Im always upfront that were going to take a non-diet approach to this, they just need to look at food differently. The real hero in this is Chantelle. I provided the tools, and she figured out how to make it sustainable for her lifestyle, and thats the key.

Free Foods

One of these tools was a list of free foods that sparked an aha moment for Chantelle. Jennifer told her all foods are okay in moderation, but free foods have very low/no carbs or calories, which allows you to eat enough to feel full.

The fun part is creating new recipes by using my free foods, Chantelle said. It became a challenge to see what I could cook and how low-carb I could get it.

Cauliflower became a favorite free food, as it readily picks up flavors in a recipe. One winning combination was a potato salad using cooked cauliflower instead of potatoes. This recipe, among many others, has been a hit with friends and family.

Making it All Work Together

Chantelles focus was to follow her providers and dietitians guidelines, including testing her blood glucose levels twice a day, every day, and staying within recommended carb counts per meal. Within three months of keeping her sugars in check, Chantelle realized she was losing weight and had more energy. When she started walking, she noticed that exercise helped decrease her sugar levels, compared to days she didnt exercise but ate the same foods.

I wasnt focused on weight loss, but its been a silver lining for keeping my sugars where they need to be, she said. When you see it all work together, its easier to stay motivated.

Motivation

Chantelles dedication to improving her health has been notable.

Chantelle was determined right from the beginning and I was so proud of her for what she has accomplished, said Lori King. As a provider I know it takes discipline, drive, and perseverance to accomplish the goals Chantelle has obtained, and I am so proud of her for taking such great care of her health.

Chantelle says her motivation has little to do with willpower. She points to the death of her mother, who passed away in 2020 due to complications of diabetes.

If I hadnt watched my mom struggle so much, I dont know if I would have been as motivated, she said. Its that nagging picture of what my mom went through amputations, dialysis, a triple bypass and I just dont feel like I have a choice. Its either do this, or end up like my mother did. If giving up something now means Im going to give up dialysis later, then its worth it.

Its not easy, but its doable, Chantelle added. I have had the best support system, and that makes a difference, too.

BCMH offers outpatient services for people living with diabetes, including nutrition counseling, free nutrition classes every first and third Tuesday of the month, and endocrinology specialty clinics. Learn more at http://www.bcmhospital.com.

More here:
BCMH the stoy of Diabetes and Determination - 921News

We are often asked to not skip meals; ever wondered why? It has been said that skipping meals can alter our blood sugar levels and make us put on weight as opposed to doing the opposite.

So, if you are an otherwise-healthy person who is looking to lose weight, do not fall for fads that suggest you avoid eating food. Why is it so?

Explaining the connection between weight, blood sugar, and meals, nutritionist Nmami Agarwal explained in an Instagram post that eating irregular meals can affect our health. The body gets surprised by too much food or no food at all, she said in a video, adding that when we skip meals, our blood sugar levels drop, which makes us overeat during our next meal.

This further makes our blood sugar levels rise quickly. There is a fluctuation highs and lows in your blood sugar levels [which can] put the body at risk of getting diabetes. And when you skip your meals and you overeat at the next meal, the excess calorie is converted into fat and stored, she warned.

According to Agarwal, this can make you gain weight. Now, the ideal thing that you can do for your body is to not skip meals and eat at a regular interval, she said.

Concurring with her, nutritionist and chef Ishti Saluja told indianexpress.com that when people focus on weight loss, they often skip meals. Yes, a calorie deficit does lead to weight loss, but it also leads to nutritional deficiencies, muscle loss and worst of all, hormonal imbalance, she said, adding that the body perceives the lack of food as a sign of stress and so, it releases stored energy to go on with the day.

But, that energy does not match up to the physical activity that is required to use that released energy, so it gets stored back as fat along with the added food that has been consumed throughout the day. This back and forth of energy going up and down due to stress and skipping meals leads to insulin resistance, among other hormonal imbalances. It causes stubborn weight around the abdomen and lower abdomen area, energy fluctuation and mood swings, she explained.

Saluja said cortisol a stress hormone dysregulation is another common side effect. Ideally, it should be at its highest level when you wake up in the morning, and should gradually go down by the time you hit the bed. But, when a person has imbalanced cortisol levels, these timings go haywire and it leads to people waking up groggy; they have a burst of energy in the evenings, making them struggle to fall asleep.

Dr Varsha Gorey, senior clinical dietitian, HOD, dietetics department at Apollo Hospitals Navi Mumbai summarised this by stating that when we starve or fast, we feel low on energy. Having a long gap [between meals] can cause an energy deficit, fatigue and dehydration. When we skip a meal and then eat, we tend to either eat too much, or the wrong kind of food, or the carbohydrate content is very high, which can lead to a sudden rise in the blood glucose level. This can make us feel lethargic. Occasionally, it is fine, but if it becomes a habit, it will impact your weight.

The importance of healthy nutrition

Dr Gorey told this outlet that we should have small and frequent meals at least four meals which are breakfast, lunch and dinner, and two mid-morning and mid-evening snacks (like fruits and nuts). Whenever you have a meal, focus on the proteins first, followed by fibre, and then carbohydrates. If we follow this pattern, it can help us control our blood sugar, weight and prevent and manage diabetes, she concluded.

For more lifestyle news, follow us on Instagram | Twitter | Facebook and dont miss out on the latest updates!

See the original post:
Can skipping a meal lead to diabetes and fat around abdomen? - The Indian Express

ReportLinker

The Global Type 2 Diabetes Drugs Market size was estimated at USD 60. 82 billion in 2021 and expected to reach USD 65. 75 billion in 2022, and is projected to grow at a CAGR 8. 38% to reach USD 98.

New York, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06342114/?utm_source=GNW 62 billion by 2027.

Market Statistics:The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:This research report categorizes the Type 2 Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the market was studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.

Based on Application, the market was studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.

Based on Distribution, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Type 2 Diabetes Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 2 Diabetes Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 2 Diabetes Drugs Market, including Abbott Laboratories, Amgen Inc., AstraZeneca Plc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Daiichi Sankyo Co. Ltd, Eli Lilly and Co., GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk AS, Peptron, Pfizer Inc., Sanofi Aventis A/S, Sanofi SA, Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Co. Ltd.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Type 2 Diabetes Drugs Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 2 Diabetes Drugs Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 2 Diabetes Drugs Market?4. What is the competitive strategic window for opportunities in the Global Type 2 Diabetes Drugs Market?5. What are the technology trends and regulatory frameworks in the Global Type 2 Diabetes Drugs Market?6. What is the market share of the leading vendors in the Global Type 2 Diabetes Drugs Market?7. What modes and strategic moves are considered suitable for entering the Global Type 2 Diabetes Drugs Market?Read the full report: https://www.reportlinker.com/p06342114/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

More:
Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -...

This report segments the neuropathy pain treatment market by indication (diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others) and geography (North America, Europe, APAC, South America, and Middle East and Africa)

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- One of the key trends in the neuropathy pain treatment market growth is the growing focus on emerging economies. Research institutes and vendors are focusing on tapping potential treatments in emerging economies, which will bring substantial growth opportunities. The increasing number of individuals requiring pain treatment has increased the demand for neuropathy pain treatment in countries such as China, India, and Brazil. Research institutes have also issued guidelines to address unmet needs in the treatment of pain. For instance, in APAC, a group of pain specialists has created tailored guidelines for each region. In addition, vendors are establishing new units in emerging economies such as Brazil to expand their presence in the market. Such initiatives will drive market growth during the forecast period.

Technavio has announced its latest market research report titled Global Neuropathy Pain Treatment Market 2022-2026

The global neuropathy pain treatment market size is expected to grow by USD 3.81 billion between 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 9.18%, according to Technavio's latest market report.

Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample reportis available in PDF format

Neuropathy Pain Treatment Market: Market Segmentation

By indication, the diabetic neuropathy segment will be the largest contributor to market growth during the forecast period. Most of the currently approved therapies provide only symptomatic relief. Hence, there is a need for disease-modifying treatments that might slow, prevent, or reverse the progression of nerve damage. Vendors are extensively focusing on R&D activities to address this unmet medical need. For instance, in January 2019, Daiichi Sankyo Company received marketing approval in Japan for the Tarlige drug for the treatment of peripheral neuropathic pain.

Story continues

In terms of geography, North America will present significant opportunities for market vendors due to the factors such as the growing prevalence of diabetes. The region will account for 33% of the market's growth during the forecast period. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the neuropathy pain treatment market in North America.

Neuropathy Pain Treatment Market: Major Growth Drivers

The focus on the development of novel therapeutics for postherpetic neuralgia is driving the neuropathy pain treatment market growth. Postherpetic neuralgia is a complication of shingles caused by the chickenpox virus. There are various drugs for the treatment of postherpetic neuralgia. However, the lack of effective therapeutics has negatively impacted the adoption rates. Therefore, vendors are focusing on the development of potential alternatives. Currently, there are around nine molecules for the treatment of postherpetic neuralgia in different stages of development. Such developments will fuel the growth of the global neuropathy pain treatment market growth during the forecast period.

Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Neuropathy Pain Treatment Market: Key Vendors

Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr. Reddys Laboratories Ltd, Eli Lilly, and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, VistaGen Therapeutics Inc., among others, are the main players in the market.

Neuropathy Pain Treatment Market: Reasons to Buy Our Report

CAGR of the market during 2022-2026

Detailed information on factors that will help the neuropathy pain treatment market grow during the next five years

Approximation of the neuropathy pain treatment market size and its contribution to the parent market

Forecasts on upcoming trends and changes in consumer behavior

The growth of the neuropathy pain treatment market across North America, Europe, APAC, South America, and Middle East and Africa

Analysis of the market's competitive landscape and detailed information on vendors

Comprehensive details of factors that will challenge the growth of neuropathy pain treatment market vendors

Related Reports

Consumer Healthcare Marketby Product and Geography - Forecast and Analysis 2022-2026: The consumer healthcare market share is expected to increase by USD 123.78 billion from 2021 to 2026.

Periodontal Dental Services Marketby End-user, Service, and Geography - Forecast and Analysis 2022-2026:The periodontal dental services market share is expected to increase by USD 10.61 billion from 2021 to 2026.

Neuropathy Pain Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.18%

Market growth 2022-2026

USD 3.81 billion

Market structure

Fragmented

YoY growth (%)

11.03

Regional analysis

North America, Europe, APAC, South America, and Middle East and Africa

Performing market contribution

North America at 33%

Key consumer countries

US, Canada, India, Germany, and UK

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd, Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, and VistaGen Therapeutics Inc.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health CareMarket Reports

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Indication

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.comWebsite: http://www.technavio.com/

Global Neuropathy Pain Treatment Market 2022-2026

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-3-81-bn-growing-focus-on-emerging-economies-to-be-a-key-trend---technavio-301639122.html

SOURCE Technavio

See original here:
Neuropathy Pain Treatment Market Size to Grow by USD 3.81 Bn, Growing Focus on Emerging Economies to be a Key Trend - Technavio - Yahoo Finance

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- The Global Pregabalin Market by Application and Geography Forecast and Analysis 2022-2026 size is expected to grow by USD 153.03 million from 2022 to 2026, at a CAGR of 3.74%. The increasing presence of a large patient pool related to neuropathic pain, the increasing geriatric population, and the rising applications of pregabalin in various diseases are themajor factors propelling the market growth. However, the growing preference for alternatives and stringent regulatory policies may impede market growth. To get more insights on drivers and challenges Request a Sample PDF

Technavio has announced its latest market research report titled Global Pregabalin Market 2022-2026

Key Market Dynamics:

Market Driver: The presence of a large patient pool related to neuropathic pain is one of the key drivers supporting thepregabalin market growth.Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There have been growing cases of these disorders, especially in the geriatric population. Meanwhile, the increasing number of individuals preferring chemotherapy for cancer treatment is fueling cases of chemotherapy-induced pain. Furthermore, according to the CDC, the incidence of shingles is approximately four per 1,000 US population annually. Overall, there are an estimated one million cases of herpes zoster in the US annually. Such a scenario will lead to an increase in the adoption of pregabalin, which, in turn, will drive the growth of the market during the forecast period.

Market Challenges: Growing preference for alternatives is one of the key factors hindering thepregabalin market growth.As the current treatments are associated with many unmet needs, end-users are looking to shift to alternative therapies. For instance, diabetic neuropathic pain can be reduced by supplementing essential acids, alpha-lipoic acid, gamma-linolenic acid, and omega-3 fatty acids. Similarly, acupuncture can be an effective way to manage peripheral neuropathy. Acupuncture uses pressure points across the body to realign the body's energy.Thus, the use of these alternative therapies may hinder growth prospects in the forecast period.

To get insights about additional key drivers, trends, and challenges available with Technavio.Read our Sample Report right now!

Market Segmentation

North Americawill be the leading region with 36% of the market's growth during the forecast period. The US and Canada are the key countries for the pregabalin market inNorth America. The increase in the older population, coupled with the established adoption of LYRICA and Cymbalta in new indications and the introduction of new drugs for the treatment of neuropathic pain, will facilitate thepregabalin market growth in North America over the forecast period.

The Neuropathic pain application segment will contribute the highest market share growth during the forecast period. Neuropathic pain affects 20% to 30% of diabetic neuropathy patients. Thus, the demand for pregabalin is rising due to more occurrences of diabetic neuropathy, which is boosting the growth of the market.Pregabalin is an alternative treatment for people with neuropathic pain that has not responded to other drugs.It effectively reduces the symptoms of numerous neuropathic pain conditions and positions itself as a first-line therapy option with exceptional safety and efficacy.These factors will drive segment growth during the forecast period.

View our sample reportfor additional insights into the contribution of all the segments, and regional opportunities in the report.

Some Companies Mentioned with their Offerings

Related Reports:

Pharmaceuticals Wholesale and Distribution Market by Types of Drugs and Geography Forecast and Analysis 2021-2025

Marine Pharmaceuticals Market by Product and Geography Forecast and Analysis 2022-2026

Pregabalin Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 3.74%

Market growth 2022-2026

USD 153.03 million

Market structure

Fragmented

YoY growth (%)

3.27

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key consumer countries

US, Canada, Germany, China, Japan, and Republic of Korea

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Biomax Biotechnics Pvt.Ltd., Camber Pharmaceuticals Inc., Cipla Ltd., Dr. Kumars Pharmaceuticals, Genesis Biotec Inc., H. L. Healthcare Pvt. Ltd., Lupin Ltd, Medley Pharmaceuticals Ltd., MK Medicine, MSN Laboratories, Neuracle Lifesciences Pvt. Ltd., Novartis AG, Pfizer Inc., Phoenix Biologicals Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Swastik Life Sciences, Torrent Pharmaceuticals Ltd., and Vibcare Pharma Pvt. Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email:media@technavio.comWebsite:www.technavio.com/

Global Pregabalin Market 2022-2026

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/pregabalin-market-to-grow-by-usd-153-03-mn-from-2022-to-2026--driven-by-presence-of-large-patient-pool-related-to-neuropathic-pain---technavio-301640610.html

SOURCE Technavio

Read more:
Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo...

Feldman, E. L., Nave, K., Jensen, T. S. & Bennett, D. L. H. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron 93, 12961313 (2017).

CAS PubMed PubMed Central Google Scholar

Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L. & Feldman, E. L. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol. 11, 521534 (2012).

PubMed PubMed Central Google Scholar

Jensen, T. S. & Finnerup, N. B. Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms. Lancet Neurol. 13, 924935 (2014).

PubMed Google Scholar

Truini, A., Garcia-Larrea, L. & Cruccu, G. Reappraising neuropathic pain in humansHow symptoms help disclose mechanisms. Nat. Rev. Neurol. 9, 572582 (2013).

CAS PubMed Google Scholar

Gandhi, R. A. & Selvarajah, D. Understanding and treating painful diabetic neuropathy: Time for a paradigm shift. Diabet. Med. 32, 771777 (2015).

CAS PubMed Google Scholar

Harris, K., Boland, C., Meade, L. & Battise, D. Adjunctive therapy for glucose control in patients with type 1 diabetes. Diabetes Metab. Syndr. Obes. 11, 159173 (2018).

CAS PubMed PubMed Central Google Scholar

Yagihashi, S., Mizukami, H. & Sugimoto, K. Mechanism of diabetic neuropathy: Where are we now and where to go?. J. Diabetes Investig. 2, 1832 (2011).

CAS PubMed Google Scholar

Lee, A. Y. & Chung, S. S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 13, 2330 (1999).

CAS PubMed Google Scholar

Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813820 (2001).

ADS CAS PubMed Google Scholar

Yan, L.-J. Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. J. Diabetes Res. 2014, 137919 (2014).

PubMed PubMed Central Google Scholar

Schreiber, A. K., Nones, C. F. M., Reis, R. C., Chichorro, J. G. & Cunha, J. M. Diabetic neuropathic pain: Physiopathology and treatment. World J. Diabetes. 6, 432444 (2015).

PubMed PubMed Central Google Scholar

Thornalley, P. J. Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. Int. Rev. Neurobiol. 50, 3757 (2002).

CAS PubMed Google Scholar

Juranek, J., Ray, R., Banach, M. & Rai, V. Receptor for advanced glycation end-products in neurodegenerative diseases a bad reputation. Rev. Neurosci. 26, 691698 (2015).

PubMed Google Scholar

Greene, D. A., Stevens, M. J., Obrosova, I. & Feldman, E. L. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur. J. Pharmacol. 375, 217223 (1999).

CAS PubMed Google Scholar

Pop-Busui, R., Sima, A. & Stevens, M. Diabetic neuropathy and oxidative stress. Diabetes Metab. Res. Rev. 22, 257273 (2006).

CAS PubMed Google Scholar

Ishii, D. N. & Lupien, S. B. Insulin-like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats. J. Neurosci. Res. 40, 138144 (1995).

CAS PubMed Google Scholar

Fernyhough, P. & Calcutt, N. A. Abnormal calcium homeostasis in peripheral neuropathies. Cell Calcium 47, 130139 (2010).

CAS PubMed Google Scholar

Koya, D. et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Investig. 100, 115126 (1997).

CAS PubMed PubMed Central Google Scholar

Akude, E. et al. Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes 60, 288297 (2011).

CAS PubMed Google Scholar

Chowdhury, S. K. R. et al. Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment. Diabetes 59, 10821091 (2010).

CAS PubMed PubMed Central Google Scholar

Younger, D. S., Rosoklija, G., Hays, A. P., Trojaborg, W. & Latov, N. Diabetic peripheral neuropathy: A clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve. 19, 722727 (1996).

CAS PubMed Google Scholar

Tomlinson, D. R. & Gardiner, N. J. Diabetic neuropathies: Components of etiology. J. Peripher. Nerv. Syst. 13, 112121 (2008).

CAS PubMed Google Scholar

Satoh, J., Yagihashi, S. & Toyota, T. The possible role of tumor necrosis factor- in diabetic polyneuropathy. Exp. Diabesity Res. 4, 6571 (2003).

PubMed PubMed Central Google Scholar

Yamagishi, S.-I. et al. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J. Neurochem. 104, 491499 (2008).

CAS PubMed Google Scholar

Du, Y. et al. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Investig. Ophthalmol. Vis. Sci. 51, 21582164 (2010).

Google Scholar

Seger, R. & Krebs, E. G. The MAPK signaling cascade. FASEB J. 9, 726735 (1995).

CAS PubMed Google Scholar

Lewis, T. S., Shapiro, P. S. & Ahn, N. G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49139 (1993).

Google Scholar

Widmann, C., Gibson, S., Jarpe, M. B. & Johnson, G. L. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 79, 143180 (1999).

CAS PubMed Google Scholar

Obata, K. & Noguchi, K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci. 74, 26432653 (2004).

CAS PubMed Google Scholar

Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 19111912 (2002).

ADS CAS PubMed Google Scholar

Krishna, M. & Narang, H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol. Life Sci. 65, 35253544 (2008).

CAS PubMed Google Scholar

Yang, S.-H., Sharrocks, A. D. & Whitmarsh, A. J. Transcriptional regulation by the MAP kinase signaling cascades. Gene 320, 321 (2003).

CAS PubMed Google Scholar

Bonny, C., Borsello, T. & Zine, A. Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases. Rev. Neurosci. 67, 5767 (2005).

Google Scholar

Tsuda, M., Ueno, H., Kataoka, A., Tozaki-Saitoh, H. & Inoue, K. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 56, 378386 (2008).

PubMed Google Scholar

Wodarski, R., Clark, A. K., Grist, J., Marchand, F. & Malcangio, M. Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur. J. Pain 13, 807811 (2009).

CAS PubMed Google Scholar

Manning, A. M. & Davis, R. J. Targeting JNK for therapeutic benefit: From junk to gold?. Nat. Rev. Drug Discov. 2, 554565 (2003).

CAS PubMed Google Scholar

Agell, N., Bachs, O., Rocamora, N. & Villalonga, P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. 4, 649654 (2002).

Google Scholar

White, C. D. & Sacks, D. B. Regulation of MAP kinase signaling by calcium. Methods Mol. Biol. 661, 151165 (2010).

CAS PubMed Google Scholar

Rosen, L. B., Ginty, D. D., Weber, M. J. & Greenberg, M. E. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 12, 12071221 (1994).

CAS PubMed Google Scholar

Purves, T. et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. 15, 25082514 (2001).

CAS PubMed Google Scholar

Price, S. A., Agthong, S., Middlemas, A. B. & Tomlinson, D. R. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: Interactions with aldose reductase. Diabetes 53, 18511856 (2004).

CAS PubMed Google Scholar

Tsuda, M., Mizokoshi, A., Shigemoto-Mogami, Y., Koizumi, S. & Inoue, K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45, 8995 (2004).

PubMed Google Scholar

Daulhac, L. et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-d-aspartate-dependent mechanisms. Mol. Pharmacol. 70, 12461254 (2006).

CAS PubMed Google Scholar

Piao, Z. G. et al. Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 121, 219231 (2006).

CAS PubMed Google Scholar

Xu, J.-T. et al. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp. Neurol. 204, 355365 (2007).

CAS PubMed Google Scholar

Cheng, H.-L. & Feldman, E. L. Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I. J. Biol. Chem. 273, 1456014565 (1998).

CAS PubMed Google Scholar

Cheng, C. & Zochodne, D. W. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52, 23632371 (2003).

CAS PubMed Google Scholar

Vincent, A. M., McLean, L. L., Backus, C. & Feldman, E. L. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J. 19, 638640 (2005).

CAS PubMed Google Scholar

Senning, E. N. & Gordon, S. E. Activity and Ca2+ regulate the mobility of TRPV1 channels in the plasma membrane of sensory neurons. Elife 4, e03819 (2015).

PubMed PubMed Central Google Scholar

Way, K. J., Katai, N. & King, G. L. Protein kinase C and the development of diabetic vascular complications. Diabet. Med. 18, 945959 (2001).

CAS PubMed Google Scholar

See the original post:
Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics...